BRIEF-Alchemab Therapeutics Signs Landmark $415M Licensing Agreement For ATLX-1282 With Eli Lilly And Company

Reuters
06 May
BRIEF-Alchemab <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Signs Landmark $415M Licensing Agreement For ATLX-1282 With Eli Lilly And Company

May 6 (Reuters) - Eli Lilly and Co LLY.N:

  • ALCHEMAB THERAPEUTICS SIGNS LANDMARK $415M LICENSING AGREEMENT FOR ATLX-1282 WITH ELI LILLY AND COMPANY

  • ALCHEMAB THERAPEUTICS: AGREEMENT WITH LILLY TO LICENSE ATLX-1282

Source text: ID:nPredn2mba

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10